Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Biogen Idec to acquire Fumapharm AG; Consolidates ownership of oral compound BG-12 being studied for multiple sclerosis
Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of BIIB033 in Subjects With Relapsing Forms of Multiple Sclerosis When Used Concurrently With Avonex (SYNERGY)
ACRM I American Congress of Rehabilitation
Clinical efficacy of BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: subgroup analyses of the DEFINE study.
Efficacy of flupirtine on cognitive function in patients with CJD: A double-blind study.
Bidirectional cytokine interactions in the maternal-fetal relationship: is successful pregnancy a TH2 phenomenon?
MS disease activity in RESTORE: A randomized 24-week natalizumab treatment interruption study.
Extracellular Cues Influencing Oligodendrocyte Differentiation and (Re)myelination.
Comparative efficacy of interferon β versus glatiramer acetate for relapsing-remitting multiple sclerosis.
Pregnancy and multiple sclerosis.
De- and remyelination in the CNS white and grey matter induced by cuprizone: the old, the new, and the unexpected.
Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial.
A New Colour Reaction on Copper and Certain Carbonyl Compounds
Meta-analysis of adverse events in recent randomized clinical trials for dimethil fumarate, glatiramer acetate and teriflunomide for the treatment of relapsing forms of multiple sclerosis.
Neuroprotective dimethyl fumarate synergizes with immunomodulatory interferon beta to provide enhanced axon protection in autoimmune neuroinflammation.
Cost Effectiveness of Fingolimod, Teriflunomide, Dimethyl Fumarate and Intramuscular Interferon-β1a in Relapsing-Remitting Multiple Sclerosis.
Inhibition of LINGO-1 promotes functional recovery after experimental spinal cord demyelination.
Episode 4 with Dr. Michael Racke on the Kir4.1 potassium channel
Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial.
National MS Society: Research Grants
Comparative effectiveness of fingolimod versus interferons or glatiramer acetate for relapse rates in multiple sclerosis: a retrospective US claims database analysis.
MS Research Roundup: An Introduction
Cost-effectiveness of delayed-release dimethyl fumarate for the treatment of relapsing forms of multiple sclerosis in the United States.
Status spongiosus of CNS and hepatic changes induced by cuprizone (biscyclohexanone oxalyldihydrazone).
Risk of early relapse following the switch from injectables to oral agents for multiple sclerosis.

Pages